Ocrelizumab in patients with Relapsing-Remitting Multiple Sclersosis (RRMS)

Trial Status
Open for Enrollment

What is the Purpose of this Study?
To investigate the effect of ocrelizumab given as two doses of 600 or 1000mg intravenously on the total number of brain lesions observed on MRI scans .

Who is Eligible to Participate?
Patients 18-55 years of age diagnosed with MS and have had two documented relapses within the last three years. Patients can not be on any beta interferons, or received previous treatment with rituximab. Patients must also meet all other inclusion and exclusion criteria explained in detail by the study coordinator.

What is involved in this Study?
Patients will be randomized to a 1:1:1:1 treatment arm. Group A will be treated with 1000mg of IV ocrelizumab Group B will be treated with 600 mg of IV ocrelizumab. Group C will receive placebo and Group D will receive intramuscular Avonex; however, a more in depth treatment period will be given in greater detail by the study coordinator.

How long is the Study?
All patients will undergo 96 weeks of study treatment representing four treatment cycles every 24 weeks. Followed by a 24 week treatment free period and a 24 week observational period. The total study duration is approximately 172 weeks.

For More Information Contact: Nicole C. Hank, MHSM, study coordinator, at 602-258-3354 ext 137 or nhank@pnal.net or call the Main line at 602-258-3354